Arlene Weintraub

Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.

Recent posts

TrueOffice Turns Boring Corporate Training Into a Game

It’s the memo every new employee dreads: “We need you to go to a drab, windowless conference room for a half-day session on compliance. During the meeting, we’ll bore you with... Read more »
Lantos Raises $3.8M to Push 3D Ear Scanner Closer to Market

When Cambridge, MA-based Lantos Technologies filed SEC documents earlier this month indicating that it raised $3.8 of a planned $6.6 million funding round, the company was pretty much mum on the... Read more »
Bluebird Bio Snags $60M From Existing VCs and Newcomers Like Shire

Cambridge, MA-based Bluebird Bio said today it raised $60 million in an oversubscribed Series D financing to further development and testing of its gene therapy platform to treat severe genetic diseases.... Read more »
Pet Dogs Help Biotech Startups Find New Weapons to Fight Cancer

A few weeks back, a black-and-white terrier mix named Chance entered a clinical trial for a drug that may offer a completely new way to combat cancer—not only in dogs, but... Read more »
From One Japanese Backer to Another: Galenea Advances Brain Drugs

When Cambridge, MA-based Galenea wrapped up a five-year, $90 million partnership with Japanese pharma company Otsuka in 2011, CEO Mark Benjamin feared the biotech’s days might be numbered. “We thought if... Read more »
From Big Data to Games: NYC Startups Pitch FinTech Innovations

For the second year in a row, New York’s FinTech Innovation Lab is holding its demo day during a brutal heat wave. But perhaps the weather serves as an apropos metaphor:... Read more »
Stealthy Gen9 Rolls Out BioFab for Large-Scale Gene Manufacturing

For the past three years, Cambridge, MA-based Gen9 has been quietly building something that its founders believe has been sorely lacking in biotech: an affordable and efficient way to synthesize genes... Read more »
WebCollage Takes Ad Copy Mobile for Top Retailers

If you click to the product page for L’Oreal Healthy Look Sublime Mousse medium brown hair color on Walgreens.com, you’ll pull up a detailed product description, a list of ingredients, and... Read more »
ImmunoGen Emerges from Genentech’s Shadow With Novel Cancer Drugs

When ImmunoGen (NASDAQ: IMGN) said yesterday that it had started human trials of a new drug to treat ovarian cancer and other solid tumors, the announcement marked a coming out... Read more »
MedStartr Offers Crowdfunding for Health IT Firms, Including Itself

A couple years ago, when Alex Fair was tossing around ideas on how to raise money for his new healthcare marketplace, FairCareMD, he knew that putting the startup on the uber-popular... Read more »
Lux Bio Resurfaces With Defined Path for Pill for Rare Eye Disease

After Lux Biosciences announced in August 2010 that the FDA declined to approve its experimental drug to treat an inflammatory disorder of the eye called uveitis, the company pretty much went... Read more »
PetFlow Paws its Way to the Top of Facebook, Sniffs Out Growth Path

In February 2011, the website Business Insider quoted PetFlow.com co-founder Alex Zhardanovsky criticizing the pioneer of the online pet-supply business—Pets.com, which famously blasted onto the Web in the early 2000s and... Read more »
Ventrus Struggles to Reassure Street After Loss of Hemorrhoid Drug

When New York-based Ventrus Biosciences went public in December 2010, the promise that the company might have the first FDA-approved prescription drug to treat hemorrhoids sent the stock from $6 to... Read more »
NPS Rejiggers Amgen Deal, Sees $75M Extra Cash

Bedminster,NJ-based NPS Pharmaceuticals (NASDAQ: NPSP) said today it had amended its licensing agreement with biotech giant Amgen (NASDAQ: AMGN) for sales of cinacalcet HCl (Sensipar), a drug used to treat secondary hyperparathyroidism.... Read more »
Corporate VC Investing Drops in Q1, Mobile Funding Poised to Jump

Deals made by the venture capital arms of major companies fell for the fourth straight quarter—a clear sign that corporate VCs are being more conservative than independent investment firms are—according to... Read more »
NJ Shocker: Roche to Shutter Nutley R&D Site

Swiss drug giant Roche said today it would close its 80-year-old research site in Nutley, NJ—a move that will slash 1,000 jobs in the U.S., as the company consolidates its R&D... Read more »
Roche Deal Gives Seaside a Leg Up in Autism Race

Two years ago, Xconomy pinpointed a growing “autism mini-cluster” in Boston—a bevy of startups seeking to develop drugs to treat the condition and other brain disorders. Now one resident of... Read more »
NPS Rallies as Good News Flows for Two Rare-Disease Drugs

Shares of Bedminster, NJ-based NPS Pharmaceuticals (NASDAQ: NPSP) jumped 14 percent to $8.21 on Friday after a panel of drug experts in Europe recommended that the regulatory agency there approve teduglutide... Read more »
Gamification Hits Healthcare as Startups Vie for Cash and Partners

Would working out at the gym be easier if you earned cash every time you hopped on the treadmill? Boston-based startup GymPact is betting that millions of Americans will answer that... Read more »
Context Matters Helps Pharma Execs Make Sense of Drug Data

S. Yin Ho, founder and CEO of New York-based pharmaceutical data provider Context Matters, isn’t impressed with all the entrepreneurial excitement around “big data”—the effort to lasso all the information being... Read more »

Page 2 of 22 « previous page · next page »

Arlene Weintraub

Recent posts

Underwriters and Partners

Xconomy Events Across the Network

Connect with Xconomy

Xconomy’s Most Popular

Xconomy on Demand